

Please try another search
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
Name | Age | Since | Title |
---|---|---|---|
Timothy R. Pearson | 53 | 2014 | Independent Chairman of the Board |
Patricia S. Andrews | 62 | 2017 | Independent Director |
Scott T. Jackson | 56 | 2018 | Independent Director |
Scott Koenig | 69 | 2017 | Independent Director |
Harout Semerjian | 52 | 2021 | CEO, President & Director |
Daniel M. Junius | 71 | 2016 | Independent Director |
Rachel K. King | 64 | 2003 | Co-Founder & Director |
Mark A. Goldberg | 69 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review